SOURCE: Pipex Pharmaceuticals, Inc.

November 06, 2007 07:30 ET

Pipex Pharmaceuticals Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

ANN ARBOR, MI--(Marketwire - November 6, 2007) - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced that it will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference today at 9:30 a.m. Eastern Time at the New York Palace Hotel. Steve H. Kanzer, Chairman and Chief Executive Officer, will make the presentation.

Mr. Kanzer will give an overview of Pipex's late-stage product candidates, as well as provide an update on the proposed NDA filing for COPREXA, Pipex's lead product for the treatment of initially presenting neurologic Wilson's disease, an orphan central nervous system (CNS) disease of copper dyshomeostasis.

Additionally, Dr. George Brewer, Professor Emeritus of Human Genetics at the University of Michigan and inventor of COPREXA will be part of a scientific panel session entitled "Orphan Neurological Diseases: A Short Cut Worth Taking," held on Wednesday, November 7th at 7:30am.

Our presentation will be webcast and accessible at the Investor Relations section of the Pipex's website located at www.pipexinc.com.

About Pipex Pharmaceuticals, Inc.

Pipex Pharmaceuticals, Inc. ("Pipex") is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases. Pipex's strategy is to exclusively in-license proprietary, clinical-stage drug candidates and complete the further clinical testing, manufacturing and regulatory requirements sufficient to seek marketing authorizations via the filing of New Drug Applications (NDAs) with the FDA in the U.S. and Marketing Application Authorizations (MAAs) with the European Medicines Evaluation Agency (EMEA). For further information, please visit, www.pipexpharma.com.

Contact Information

  • For Further Information Contact:

    Steve H. Kanzer, CPA, Esq.
    Chairman and Chief Executive Officer
    (734) 332-7800

    Thomas Redington
    (Investor Relations)
    Redington Inc.
    203-222-7399
    www.redingtoninc.com